药石科技(300725) - 300725药石科技投资者关系管理信息20250428(2)

Financial Performance - Total revenue for 2024 was 1.689 billion CNY, a decrease of 2.12% year-on-year [6] - Operating cash flow increased by 22.68% to 303 million CNY [6] - Net profit attributable to shareholders rose by 11.24% to 220 million CNY [6] - Earnings per share reached 1.10 CNY, an increase of 12.43% [6] - Gross margin was 38.06%, down by 4.46 percentage points year-on-year [6] Revenue Breakdown - Revenue from drug development and commercialization was 1.354 billion CNY, down 1.83% year-on-year [8] - Revenue from drug research stage products and services was 331 million CNY, a decrease of 4.06% [8] - Revenue from molecular building blocks for drug discovery was 281 million CNY; for drug development and production, it was 491 million CNY [9] Customer Segmentation - Revenue sources by type: 28% from large multinational pharmaceutical companies and 72% from small and medium-sized biopharmaceutical companies [12] - Revenue sources by region: North America contributed 58% (979 million CNY), Europe 11% (193 million CNY), China 27% (449 million CNY), and Japan/Korea and others 4% (68 million CNY) [12] Project Pipeline - Over 2,400 projects in various stages, with 78 projects in clinical phases [15] - Focus on early clinical projects to strengthen later-stage project growth [14] Innovation and Technology - Cumulative design of over 200,000 novel molecular building blocks, with over 45,000 compounds synthesized [23] - Development of unique solutions to accelerate new drug research, including an AI-driven drug discovery platform [27] - Continuous flow chemistry and low-carbon technology innovations are key to sustainable development [50] ESG Commitment - Achieved AA rating in Wind ESG assessment and joined the UN Global Compact [72] - Received multiple awards for sustainability and green chemistry excellence [52] Future Strategy - Focus on enhancing customer value creation and strengthening technology transformation capabilities [75] - Aim to improve delivery quality and build trust with customers [76]